Posted by Michael Wonder on 07 Mar 2017
Actelion is granted marketing authorisation by the European Commission for Ledaga (chlormethine gel) for the treatment of MF-CTCL
7 March 2017 - Actelion announced today that the European Commission has granted marketing authorisation for the use of Ledaga (chlormethine gel) 160 micrograms/g for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).
MF-CTCL is a rare, potentially life-threatening immune system cancer that is chronic and usually progresses slowly. The course of disease in individual patients is unpredictable. In about 34% of cases, a progression of the disease is observed, and in the most advanced stages, MF-CTCL cells can metastasise to other body tissues, including the liver, spleen and lungs.
Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF type CTCL) in adult patients.
